Anticoagulation in Patients With Gastrointestinal Disease.

Area of Science:

• Gastroenterology
• Cardiology
• Hematology

Background:

• Gastrointestinal (GI) disease presents a dual challenge in anticoagulation, increasing bleeding risk while maintaining thromboembolic vulnerability.
• Conditions like mucosal injury, portal hypertension, and IBD predispose to hemorrhage, while therapy interruption elevates risks of stroke, VTE, and stent thrombosis.

Purpose of the Study:

• To outline a contemporary, risk-balanced approach to managing patients with GI disease on anticoagulation.
• To compare the GI bleeding profiles of direct oral anticoagulants (DOACs).
• To detail strategies for periprocedural management, acute GI bleeding, and anticoagulation resumption.

Main Methods:

• Review of current literature and clinical guidelines for anticoagulation in GI disease.
• Analysis of DOACs' safety profiles regarding GI bleeding.
• Discussion of management strategies for acute GI bleeding and periprocedural care.

Main Results:

• A risk-balanced, indication-first approach is recommended, integrating thrombotic urgency, GI disease, and bleeding risk factors.
• DOACs have varied GI bleeding risks; apixaban appears safer in high-risk groups compared to dabigatran and rivaroxaban.
• Effective management of acute GI bleeding involves stabilization, restrictive transfusion, source control, and judicious use of reversal agents.

Conclusions:

• Adjunctive therapies like PPIs and H. pylori eradication reduce recurrent GI bleeding.
• Appropriate resumption of anticoagulation improves survival and reduces thromboembolic events.
• Further research is needed on optimal reversal, restart timing, and management in cirrhotic patients.